February 29th 2024
An oral suspension formula of Imbruvica received the green light from the Food and Drug Administration to be used in all approved indications.
Several Factors May Impact a Waldenstrom’s Macroglobulinemia Treatment Decision
November 16th 2021Without a huge difference in efficacy between many of the available treatments for Waldenstrom’s macroglobulinemia, one expert says patients and their clinicians should look to other factors when deciding which regimen is best.
Drug Duo Granted Priority Review to Treat Waldenstrom Macroglobulinemia
June 25th 2018The FDA has granted a priority review to a supplemental new drug application (sNDA) Imbruvica (ibrutinib) for use in combination with Rituxan (rituximab) as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.